<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="doi: 10.1080/21645515.2019.1638205 : Commentary A review of epidemic preparedness for" exact="influenza" post="through local vaccine production: national security for Thailand P."/>
 <result pre="way.khvi-15-10-1638205.pdf Abstract ABSTRACT Being vigilant of the potential for an" exact="influenza" post="pandemic, the Global Action Plan for Influenza Vaccines (GAP)"/>
 <result pre="the Thai government has developed its national strategic plan for" exact="influenza" post="pandemic preparedness including the plan for manufacturing influenza vaccine"/>
 <result pre="plan for influenza pandemic preparedness including the plan for manufacturing" exact="influenza" post="vaccine in Thailand. With the support of WHO, the"/>
 <result pre="Pharmaceutical Organization (GPO) as the developed local production capacity of" exact="influenza" post="vaccines. The H1N1 live attenuated influenza vaccine (LAIV) and"/>
 <result pre="local production capacity of influenza vaccines. The H1N1 live attenuated" exact="influenza" post="vaccine (LAIV) and H5N2 LAIV produced by GPO have"/>
 <result pre="its capacity to Inactivated Influenza Vaccine (IIV), aiming for sustainable" exact="influenza" post="vaccine production for national coverage. KEYWORDS Influenza vaccine live"/>
 <result pre="attenuated national security fig-count: table-count: ref-count: page-count: Current situation of" exact="influenza" post="pandemic risk and the 2009 H1N1 pandemic Since the"/>
 <result pre="pandemic Since the first human infection of highly pathogenic H5N1" exact="avian influenza" post="in Hong Kong in 1997, sporadic cases have been"/>
 <result pre="Since the first human infection of highly pathogenic H5N1 avian" exact="influenza" post="in Hong Kong in 1997, sporadic cases have been"/>
 <result pre="have been 861 confirmed human infections including 455 deaths from" exact="avian influenza" post="A(H5N1) reported from 17 countries.1 Moreover, since March 2013"/>
 <result pre="been 861 confirmed human infections including 455 deaths from avian" exact="influenza" post="A(H5N1) reported from 17 countries.1 Moreover, since March 2013"/>
 <result pre="reported from 17 countries.1 Moreover, since March 2013 when the" exact="avian influenza" post="A(H7N9) infection was first detected in humans, a total"/>
 <result pre="from 17 countries.1 Moreover, since March 2013 when the avian" exact="influenza" post="A(H7N9) infection was first detected in humans, a total"/>
 <result pre="World Health Organization (WHO). In 2006, with growing concern that" exact="avian influenza" post="viruses could mutate to become transmissible between humans and"/>
 <result pre="Health Organization (WHO). In 2006, with growing concern that avian" exact="influenza" post="viruses could mutate to become transmissible between humans and"/>
 <result pre="inactivated trivalent vaccine and 2,340 million doses of monovalent pandemic" exact="influenza" post="vaccine.2 Therefore, one of the major approaches to increasing"/>
 <result pre="one of the major approaches to increasing supplies of pandemic" exact="influenza" post="vaccine was capacity building and infrastructure strengthening or new"/>
 <result pre="agreement with WHO in 2007. At the time of the" exact="influenza" post="A(H1N1) pandemic in 2009, the first imported case of"/>
 <result pre="By the second week of June 2009, there were two" exact="influenza" post="outbreak notifications in the central region of Thailand, and"/>
 <result pre="of Thailand, and then only a few weeks later the" exact="influenza" post="virus spread throughout the country.3 At that time, there"/>
 <result pre="At that time, there was no commitment to supplying inactivated" exact="influenza" post="vaccines to Thailand during potential pandemics and there was"/>
 <result pre="potential pandemics and there was no domestic production of bulk" exact="influenza" post="vaccines. In fact, prior to 2007, there was no"/>
 <result pre="By 2010, Thailand was importing 2.1 million doses of seasonal" exact="influenza" post="vaccine: GPO-MBP, a joint venture between the Government Pharmaceutical"/>
 <result pre="(GPO) and Sanofi Pasteur, supplied approximately 800,000 doses of seasonal" exact="influenza" post="vaccine by formulating and filling imported bulk, and the"/>
 <result pre="In 2005, the Thai government issued the first national pandemic" exact="influenza" post="preparedness plans in response to the highly pathogenic avian"/>
 <result pre="pandemic influenza preparedness plans in response to the highly pathogenic" exact="avian influenza" post="outbreak in 2004. The second national strategic plan was"/>
 <result pre="influenza preparedness plans in response to the highly pathogenic avian" exact="influenza" post="outbreak in 2004. The second national strategic plan was"/>
 <result pre="for the year 2008–2010. The first national strategic plan for" exact="influenza" post="pandemic preparedness (2005–2007) focused on supporting research and development"/>
 <result pre="set up a local industrial-scale manufacture plant for egg-based pandemic" exact="influenza" post="vaccines and train personnel for industrial-scale vaccine research and"/>
 <result pre="(BARDA), the GPO has been able to develop live attenuated" exact="influenza" post="vaccine (LAIV) for potential pandemic vaccines (H1N1 and H5N2"/>
 <result pre="for potential pandemic vaccines (H1N1 and H5N2 LAIV) and inactivated" exact="influenza" post="vaccine for seasonal use. In 2009, the Thai Government"/>
 <result pre="of Experimental Medicine (IEM), Saint Petersburg, Russia. After receiving the" exact="influenza" post="A H1N1 (2009) pre-master seed from Russia through the"/>
 <result pre="the criteria for licensure for emergency use.8 GPO-manufactured live attenuated" exact="influenza" post="H5 candidate vaccine GPO had received master donor seed"/>
 <result pre="was culture-positive on day 1 after the 2nd immunization. No" exact="influenza" post="virus was isolated from Madin-Darby Canine Kidney epithelial (MDCK)"/>
 <result pre="to evaluate the immune response and safety of live attenuated" exact="influenza" post="H5 vaccine candidate strain A/17/turkey/Turkey/05/133 (H5N2) manufactured by GPO"/>
 <result pre="environment with the vaccine strain. Two doses of live attenuated" exact="influenza" post="H5 vaccine candidate strain A/17/turkey/Turkey/05/133 (H5N2) were given by"/>
 <result pre="study conducted in the US by K. Subbarao showed that" exact="influenza" post="A(H5N1) pLAIV recipients with poor primary immune responses were"/>
 <result pre="having a long-lasting immunity and could be boosted with inactivated" exact="influenza" post="H5N1 vaccine at 52, 54 or 56 months after"/>
 <result pre="study The booster vaccine used was subunit aluminum hydroxide adsorbed" exact="influenza" post="vaccine containing HA and NA proteins from the influenza"/>
 <result pre="adsorbed influenza vaccine containing HA and NA proteins from the" exact="influenza" post="virus A/turkey/Turkey/1/05 (H5N1). Sixty participants (40 vaccinees, 20 placebos"/>
 <result pre="been enrolled and received one dose of the H5 inactivated" exact="influenza" post="vaccine (IIV) 1 year after the H5N2 vaccination. The"/>
 <result pre="are described in our previous report.10 Efforts in manufacturing inactivated" exact="influenza" post="vaccines (IIVs) Following experience with the successful clinical trials"/>
 <result pre="experience with the successful clinical trials of the H5N2 live-attenuated" exact="influenza" post="vaccine and obtaining the licensure for its pandemic use"/>
 <result pre="seroconversion rate of participants who had received the GPO trivalent-inactivated" exact="influenza" post="vaccine 21 days later were 85%, 45%, and 95%"/>
 <result pre="manufacturer (the GPO) to be able to manufacture its own" exact="influenza" post="vaccines as a part of the strategy of self-reliance"/>
 <result pre="have the capacity to produce 2 million doses of seasonal" exact="influenza" post="vaccines, then to increase to 10 million doses in"/>
 <result pre="of the study; Microgen (Moscow, Russia) for providing the inactivated" exact="influenza" post="vaccine used in part 2; the clinical and nursing"/>
 <result pre="References References 1.collab: WHOCumulative number of confirmed human cases for" exact="avian influenza" post="A(H5N1) reported to WHO, 2003–2018. Geneva, Switzerland: WHO/GIP; 2018."/>
 <result pre="References 1.collab: WHOCumulative number of confirmed human cases for avian" exact="influenza" post="A(H5N1) reported to WHO, 2003–2018. Geneva, Switzerland: WHO/GIP; 2018."/>
 <result pre="to WHO, 2003–2018. Geneva, Switzerland: WHO/GIP; 2018. 2.collab: WHOGlobal pandemic" exact="influenza" post="action plan to increase vaccine supply. Geneva, Switzerland: WHO;"/>
 <result pre="AkarasewiP, YingyongT, SuthachanaS, PittayawonganonC, UngchusakK.Three waves of the 2009 H1N1" exact="influenza" post="pandemic in Thailand. Siriraj Med J. 2011;63:64–67. 4.The National"/>
 <result pre="PandemicThe second national strategic plan for prevention and control of" exact="avian influenza" post="and preparedness for influenza pandemic. Bangkok, Thailand: The Ministry"/>
 <result pre="second national strategic plan for prevention and control of avian" exact="influenza" post="and preparedness for influenza pandemic. Bangkok, Thailand: The Ministry"/>
 <result pre="for prevention and control of avian influenza and preparedness for" exact="influenza" post="pandemic. Bangkok, Thailand: The Ministry of Public Health; 2008."/>
 <result pre="HeXS, GreenbergHB.Distinct cross-reactive B-cell responses to live attenuated and inactivated" exact="influenza" post="vaccines. J Infect Dis. 2014;210:865–74. doi:10.1093/infdis/jiu190.24676204 7.ClementsML, MurphyBRDevelopment and"/>
 <result pre="systemic antibody responses in adults given live attenuated or inactivated" exact="influenza" post="A virus vaccine. J Clin Microbiol. 1986;23:66–72.3700610 8.PhonratB, PitisuttithumP,"/>
 <result pre="WibulpolprasertSSafety and immune responses following administration of H1N1 live attenuated" exact="influenza" post="vaccine in Thais. Vaccine. 2013;31:1503–09. doi:10.1016/j.vaccine.2012.12.082.23318149 9.SurichanS, WirachwongP, SupachaturasW,"/>
 <result pre="UtidK, TheerasurakarnS, LangsanamP, LakornrachP, NitisapornL, ChansikkakornC, VangkanontaW, et alDevelopment of" exact="influenza" post="vaccine production capacity by the government pharmaceutical organization of"/>
 <result pre="government pharmaceutical organization of Thailand: addressing the threat of an" exact="influenza" post="pandemic. Vaccine. 2011;29(Suppl 1):A29–A33. doi:10.1016/j.vaccine.2011.04.120.21684425 10.PitisuttithumP, BoonnakK, ChamnanchanuntS, PuthavathanaP,"/>
 <result pre="ThanachartwetV, SilachamroonU, et alSafety and immunogenicity of a live attenuated" exact="influenza" post="H5 candidate vaccine strain A/17/turkey/Turkey/05/133 H5N2 and its priming"/>
 <result pre="LRK, BAM, RAK, KDL, QinJ, DAF, et alA live attenuated" exact="influenza" post="A(H5N1) vaccine induces long-term immunity in the absence of"/>
</results>
